Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells

被引:133
作者
De Palma, M
Montini, E
Santoni de Sio, FR
Benedicenti, F
Gentile, A
Medico, E
Naldini, L
机构
[1] San Raffaele Telethon Inst Gene Therapy, TIGET, HSR, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, H San Raffaele Sci Inst, Milan, Italy
[3] Inst Canc Res & Treatment, Turin, Italy
关键词
D O I
10.1182/blood-2004-03-0798
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent reports have indicated that human immunodeficiency virus (HIV) and murine leukemia virus (MLV) vectors preferentially integrate into active genes. Here, we used a novel approach based on genetic trapping to rapidly score several thousand integration sites and found that MLV vectors trapped cellular promoters more efficiently than HIV vectors. Remarkably, 1 in 5 MLV integrations trapped an active promoter in different cell lines and primary hematopoietic cells. Such frequency was even higher in growth-stimulated lymphocytes. We show that the different behavior of MLV and HIV vectors was dependent on a different integration pattern within transcribed genes. Whereas MLV-based traps showed a strong bias for promoter-proximal integration leading to efficient reporter expression, HIV-based traps integrated throughout transcriptional units and were limited for expression by the distance from the promoter and the reading frame of the targeted gene. Our results indicate a strong propensity of MLV to establish transcriptional interactions with cellular promoters, a behavior that may have evolved to enhance proviral expression and may increase the insertional mutagenesis risk. Promoter trapping efficiency provides a convenient readout to assess transcriptional interactions between the vector and its flanking genes at the integration site and to compare. integration site selection among different cell types and in different growth conditions. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:2307 / 2315
页数:9
相关论文
共 30 条
  • [1] Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells
    Ailles, L
    Schmidt, M
    Santoni de Sio, FR
    Glimm, H
    Cavalieri, S
    Bruno, S
    Piacibello, W
    Von Kalle, C
    Naldini, L
    [J]. MOLECULAR THERAPY, 2002, 6 (05) : 615 - 626
  • [2] RTCGD: retroviral tagged cancer gene database
    Akagi, K
    Suzuki, T
    Stephens, RM
    Jenkins, NA
    Copeland, NG
    [J]. NUCLEIC ACIDS RESEARCH, 2004, 32 : D523 - D527
  • [3] Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters
    Amendola, M
    Venneri, MA
    Biffi, A
    Vigna, E
    Naldini, L
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (01) : 108 - 116
  • [4] Gene silencing as a threat to the success of gene therapy
    Bestor, TH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) : 409 - 411
  • [5] Targeting survival: Integration site selection by retroviruses and LTR-retrotransposons
    Bushman, FD
    [J]. CELL, 2003, 115 (02) : 135 - 138
  • [6] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
    Cavazzana-Calvo, M
    Hacein-Bey, S
    Basile, CD
    Gross, F
    Yvon, E
    Nusbaum, P
    Selz, F
    Hue, C
    Certain, S
    Casanova, JL
    Bousso, P
    Le Deist, F
    Fischer, A
    [J]. SCIENCE, 2000, 288 (5466) : 669 - 672
  • [7] The future of gene therapy
    Cavazzana-Calvo, M
    Thrasher, A
    Mavilio, F
    [J]. NATURE, 2004, 427 (6977) : 779 - 781
  • [8] Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs
    Cawley, S
    Bekiranov, S
    Ng, HH
    Kapranov, P
    Sekinger, EA
    Kampa, D
    Piccolboni, A
    Sementchenko, V
    Cheng, J
    Williams, AJ
    Wheeler, R
    Wong, B
    Drenkow, J
    Yamanaka, M
    Patel, S
    Brubaker, S
    Tammana, H
    Helt, G
    Struhl, K
    Gingeras, TR
    [J]. CELL, 2004, 116 (04) : 499 - 509
  • [9] De Palma M, 2002, METHOD ENZYMOL, V346, P514
  • [10] Fischer A, 2004, NEW ENGL J MED, V350, P2526